About :

• AutoPure CK- MB is reagent kit for direct quantitative determination of CK – MB in human serum and plasma on automated clinical chemistry analyzers.
• AutoPure CK-MB is a ready-to-use, two liquid reagent system.
• With AutoPure CK – MB, the assay is linear upto 2000 IU/ (33.4 ukat/l). suitable control material prior to release*.
  To ensure the adequate quality control, it is recommended that the laboratory should use the normal and abnormal commercial reference control serum. It should be realized that the use of quality control material checks both the reagent and instrument functions together. If the control values fall outside the specified limits, each of the below criteria should be cross-checked and corrected:

• Proper instrument function – wavelength setting, light source and temperature control.
• Cleanliness of probes and cuvettes.
• Bacterial contamination of wash water used by the instrument.
• Expiry date of the reagent kit. **Brand name of Roche Diagnostics, Germany, subject to availability of control serum.

Principle :

The serum sample is incubated with CK – MB reagent containing an antibody specific to CK – M subunit which completely inhibits the CK-M monomer. The activity of CK-B which is not inhibited by the antibody, is then measured kinetically.
Collect samples using standard sampling tubes. Serum, heparinized plasma or EDTA plasma can be used. Perform the assay preferably on the same day. CK – MB activity in serum/plasma is stable for 3 days at 20– 8°C and 30 days at -20°C. Centrifuge samples containing precipitate before performing the assay.
Serum/Plasma: < 24 IU/L(0.40 ukat/l) at 37°C

Procedure :

• СК-В Creatine phosphate +ADP- –
• Creatine +ATP
• AutoPure CK – MB can be used on various automated analyzers. The procedure described below is for Sphera auto-analyzer.
• Hexokinase
• ATP+ Glucose
• Glucose-6-phosphate +ADP
• Expected range varies from population to population. It is therefore recommended that each laboratory should establish its own range. For diagnostic purposes, the CK – MB results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

Quality Control :